TRVN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders...

Stats
今日成交量	42 532.00
平均成交量	204 957
市值	7.42M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $-0.370 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0100 (2.39%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Drake Patricia M.	Buy	25 000	Common Stock
2023-12-14	Drake Patricia M.	Sell	1 835	Common Stock
2023-12-14	Drake Patricia M.	Buy	50 000	Common Stock
2023-12-14	Bourdow Carrie L.	Buy	100 000	Common Stock
2023-12-14	Bourdow Carrie L.	Sell	7 123	Common Stock

INSIDER POWER
92.75
Last 98 transactions
Buy: 7 332 092 \| Sell: 537 308

音量相关性

長: -0.20 (neutral)

短: -0.88 (strong negative)

Signal:(52.298) Neutral

Trevena Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Trevena Inc 相关性 - 货币/商品

-0.23
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.32
( neutral )

Trevena Inc 财务报表

Annual	2023
营收:	$3.13M
毛利润:	$562 000 (17.98 %)
EPS:	$-3.16

FY	2023
营收:	$3.13M
毛利润:	$562 000 (17.98 %)
EPS:	$-3.16

FY	2022
营收:	$-418 000
毛利润:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2021
营收:	$567.00
毛利润:	$-387.00 (-68.25 %)
EPS:	$-0.0101

Financial Reports:

No articles found.

Trevena Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

实时更新： Trevena Inc [TRVN]

Upcoming Earnings Alert

Trevena Inc Options Data

Calls

Puts